FWIW, I voted for "f) None of the above.". In the industry I service, Nutritional Supplements, it is widely known that CoQ10 supplementation should be strongly promoted for all those that take statin type drugs. Statin drugs inhibit the human bodies’ ability to natural synthesizes CoQ10. CoQ10 is considered an excellent supplement focused on improving "heart health". For more information, please see the following link.
I feel it is feasible that Kaneka, a Japanese company who is currently building an $80 million factory in Pasadena, Texas, may position themselves with PFE to promote a new product, a combination therapy if you will where Lipitor/CoQ10 could be lunched as a new "patented" product.
For more on Kaneka, please see the following link.
One year ago, an iHub survey (#msg-8955911) asked what will be “the most exciting thing about Pfizer during 2006.”
Those who answered with choice c) “Pipeline progress, especially for the HDL-raising drug, Torcetrapib” clearly got it right, but probably not for the reason they expected.
Market Data 
Markets 
AI
